Daiichi Sankyo’s Bid For Ranbaxy To Be Complete Soon
This article was originally published in PharmAsia News
Daiichi Sankyo President Takashi Shoda announced Oct. 8 that the company's take over bid for Ranbaxy will be completed soon. According to the offer, the company plans to acquire 50.1 percent of Ranbaxy shares. Shoda stated that the company will be able to obtain the target shares through allocation of new shares to a third party and share purchase from the founding family. Ranbaxy could become a Daiichi Sankyo subsidiary as early as the end of the year. The offer received a green light Oct.3 from the Indian government and an approval from India's central bank is expected soon. (Click here for more - Japanese language
You may also be interested in...
A flurry of financial appointments has been seen across the off-patent industry, involving major players Dr Reddy’s, Biocon, Mayne Pharma and Xbrane Biopharma.
Aurobindo has agreed to sell its US-based Natrol dietary supplements business at a significant premium to the $132.5m it paid in late 2014, as the Indian firm continues to drive into complex formulations in the US, including injectables and biosimilars.
GlaxoSmithKline’s third quarter results included a 9% decline in sales in its vaccine business, but this was offset by tight cost controls and restructuring benefits; the company expects to continue investing in its pipeline and new product launches.